Blog
Intravenous infusion of exenatide does not reduce the risk of complications in patients after heart surgery
18
Nov
Nov
A large-scale clinical trial has shown that intravenous infusion of the glucagon-like peptide-1 (GLP-1) analogue exenatide during heart surgery involving bypass does not significantly reduce the risk of death, stroke, or organ failure. Scientists today presented this preliminary, groundbreaking science study at the American Heart Association 2024 Scientific Sessions. The meeting, taking place November 16-18, […]